XTX Topco Ltd Makes New $267,000 Investment in Stoke Therapeutics, Inc. (NASDAQ:STOK)

Key Points

• XTX Topco Ltd has acquired a new position in Stoke Therapeutics, purchasing 40,181 shares valued at approximately $267,000.
• Several institutional investors have increased their stakes in Stoke Therapeutics, with GAMMA Investing LLC raising its stake by 1,842.0% in the first quarter.
• Stoke Therapeutics currently holds an average rating of "Buy" from analysts, with a target price ranging from $22.00 to $30.00.

XTX Topco Ltd bought a new stake in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 40,181 shares of the company's stock, valued at approximately $267,000. XTX Topco Ltd owned approximately 0.07% of Stoke Therapeutics as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. JPMorgan Chase & Co. grew its holdings in Stoke Therapeutics by 29.2% during the 4th quarter. JPMorgan Chase & Co. now owns 19,964 shares of the company's stock valued at $220,000 after buying an additional 4,512 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Stoke Therapeutics by 1,842.0% during the 1st quarter. GAMMA Investing LLC now owns 5,360 shares of the company's stock valued at $36,000 after acquiring an additional 5,084 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Stoke Therapeutics by 123.7% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 95,505 shares of the company's stock valued at $1,053,000 after acquiring an additional 52,813 shares during the last quarter. Renaissance Technologies LLC bought a new stake in shares of Stoke Therapeutics during the 4th quarter valued at about $1,423,000. Finally, ProShare Advisors LLC bought a new stake in shares of Stoke Therapeutics during the 4th quarter valued at about $139,000.

Stoke Therapeutics Stock Up 6.1%

Shares of NASDAQ STOK traded up $1.04 during trading hours on Friday, reaching $18.21. 1,967,052 shares of the stock traded hands, compared to its average volume of 913,360. The company has a market capitalization of $997.91 million, a P/E ratio of 21.42 and a beta of 1.15. Stoke Therapeutics, Inc. has a 52-week low of $5.35 and a 52-week high of $18.45. The company's 50-day simple moving average is $12.55 and its two-hundred day simple moving average is $10.16.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.40) earnings per share for the quarter, beating analysts' consensus estimates of ($0.57) by $0.17. The company had revenue of $13.82 million for the quarter, compared to analysts' expectations of $31.51 million. Stoke Therapeutics had a return on equity of 18.32% and a net margin of 26.25%. As a group, sell-side analysts forecast that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on STOK. Needham & Company LLC reiterated a "buy" rating and set a $22.00 price target on shares of Stoke Therapeutics in a research report on Tuesday, July 1st. Jefferies Financial Group began coverage on Stoke Therapeutics in a research report on Friday, July 18th. They set a "buy" rating and a $30.00 price target for the company. Chardan Capital reiterated a "buy" rating and set a $24.00 price target on shares of Stoke Therapeutics in a research report on Wednesday. HC Wainwright dropped their price target on Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating for the company in a research report on Wednesday, May 14th. Finally, Cantor Fitzgerald upgraded Stoke Therapeutics to a "strong-buy" rating in a research report on Wednesday, May 14th. Six equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Stoke Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $25.17.

Insider Transactions at Stoke Therapeutics

In related news, insider Barry Ticho sold 6,471 shares of the firm's stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $10.03, for a total transaction of $64,904.13. Following the transaction, the insider directly owned 25,782 shares of the company's stock, valued at approximately $258,593.46. This trade represents a 20.06% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, General Counsel Jonathan Allan sold 13,712 shares of the firm's stock in a transaction dated Wednesday, August 13th. The shares were sold at an average price of $15.00, for a total value of $205,680.00. Following the transaction, the general counsel directly owned 19,631 shares in the company, valued at approximately $294,465. This represents a 41.12% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 26,432 shares of company stock worth $345,775. 9.50% of the stock is currently owned by insiders.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.